NDAOTICSUSPENSION/DROPS
Approved
Jul 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (6)
infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: • Acute Otitis Media (AOM) in pediatric patients (age 6 monthsolder) with tympanostomy tubes due to Staphylococcus aureusStreptococcus pneumoniaeHaemophilus influenzaeMoraxella catarrhalisPseudomonas aeruginosa
Clinical Trials (5)
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
Started Jan 2016
46 enrolled
BronchiectasisPulmonary Disease, Chronic Obstructive
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Started Apr 2014
521 enrolled
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Started May 2013
416 enrolled
Bronchiectasis
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Started Aug 2009
19 enrolled
Pulmonary Disease, Chronic Obstructive
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
Started Jun 2009
124 enrolled
Bronchiectasis